首页|期刊导航|中国中医药信息杂志|参芪降浊汤治疗特发性膜性肾病脾肾气虚兼血瘀证临床研究

参芪降浊汤治疗特发性膜性肾病脾肾气虚兼血瘀证临床研究OA

Clinical Study on Shenqi Jiangzhuo Decoction for the Treatment of Idiopathic Membranous Nephropathy with Spleen-kidney Qi Deficiency and Blood Stasis Syndrome

中文摘要英文摘要

目的 观察参芪降浊汤对特发性膜性肾病(IMN)脾肾气虚兼血瘀证患者临床疗效及对高凝状态、炎症免疫因子及肾间质纤维化的影响.方法 采用分层随机化方法将72例患者分为对照组和观察组各36例,2组均予免疫抑制、抗凝及降压调脂等西医基础治疗,观察组予参芪降浊汤口服,对照组予中药安慰剂口服,2组均连续治疗8周.观察2组临床疗效,比较2组治疗前后中医症状评分、肾功能指标[24 h尿蛋白定量(24 hUp)、肾小球滤过率(eGFR)、血肌酐(SCr)、血尿素氮(BUN)]、凝血指标[纤维蛋白原(FIB)、D-二聚体(D-D)、血管性血友病因子(vWF)]、炎症免疫指标[白细胞介素(IL)-6、IL-17、B淋巴细胞活化因子(BAFF)、辅助性T细胞17(Th17)/调节性T细胞(Treg)比值]、间质纤维化指标[结缔组织生长因子(CTGF)、纤维连接蛋白(FN)],监测2组血尿常规、肝功能、心电图等指标,并记录不良反应事件情况.结果 观察组总有效率为88.89%(32/36),对照组为77.78%(28/36),观察组临床疗效优于对照组(P<0.05).与本组治疗前比较,对照组治疗后下肢浮肿、尿少而浊、腰骶酸软刺痛、大便稀溏、四肢麻木、肌肤甲错评分及总分明显降低(P<0.05),观察组各项症状评分及总分均明显降低(P<0.05);2组治疗后比较,观察组下肢浮肿、尿少而浊、纳少懒言、脘腹坠胀、大便稀溏、肌肤甲错评分及总分明显低于对照组(P<0.05).与本组治疗前比较,2组治疗后24 hUp、SCr、BUN、FIB、D-D、vWF、IL-6、BAFF、CTGF、FN及Th17/Treg比值均明显降低(P<0.05),eGFR明显升高(P<0.05);2组治疗后比较,观察组24 hUp、SCr、FIB、vWF、IL-6、BAFF、FN及Th17/Treg比值明显低于对照组(P<0.05),eGFR明显高于对照组(P<0.05).对照组、观察组不良反应发生率分别为5.6%(2/36)、2.8%(1/36),差异无统计学意义(P>0.05).结论 参芪降浊汤可显著改善IMN脾肾气虚兼血瘀证患者肾功能、凝血、炎症免疫因子及间质纤维化等指标水平,延缓IMN病情进展.

Objective To observe the clinical efficacy of Shenqi Jiangzhuo Decoction in patients with idiopathic membranous nephropathy(IMN)with spleen-kidney qi deficiency and blood stasis syndrome,as well as its effects on hypercoagulable state,inflammatory factors and renal interstitial fibrosis.Methods Totally 72 patients were divided into the control group and the treatment group according to hierarchical randomization method,with 36 cases in each group.Both groups were given basic treatment such as immunosuppression,anticoagulation and blood pressure and lipid regulation.The treatment group was given oral Shenqi Jiangzhuo Decoction,while the control group received Chinese materia medica placebo orally.The treatment course for both groups was 8 weeks.The clinical efficacy of both groups was observed.The TCM syndrome scores,the indicators of renal function[24-hour urine protein quantification(24 hUp),glomerular filtration rate(eGFR),serum creatinine(SCr),blood urea nitrogen(BUN)],coagulation indicators[fibrinogen(FIB),D-dimer(D-D),von Willebrand factor(vWF)],inflammatory factor indicators[interleukin(IL)-6,IL-17,B lymphocyte activation factor(BAFF),helper T cell 17(Th17)/regulatory T cell(Treg)ratio],and interstitial fibrosis indicators[connective tissue growth factor(CTGF),laminin(FN)]of both groups before and after treatment were evaluated.The blood and urine routine,liver function,ECG and other indicators of the two groups were monitored,and the adverse events were recorded.Results The total effective rate of the treatment group was 88.89%(32/36),and that of the control group was 77.78%(28/36).The clinical efficacy of the treatment group was better than that of the control group(P<0.05).Compared with before treatment,the scores of lower extremity edema,scanty urine and clear urine,soreness and stabbing pain in the waist and sacrum,loose stools,numbness in limbs,and skin and nail changes in the control group decreased significantly after treatment(P<0.05),the symptom scores of the treatment group decreased significantly(P<0.05);after treatment,the scores of lower extremity edema,scanty urine and clear urine,poor appetite and laziness in speech,abdominal distension,loose stools,skin and nail changes in the treatment group were significantly lower than the control group(P<0.05).Compared with before treatment,the 24 hUp,SCr,BUN,FIB,D-D,vWF,IL-6,BAFF,CTGF,FN and the ratio of Th17/Treg in both groups decreased significantly after treatment(P<0.05),and the eGFR level increased significantly(P<0.05);after treatment,the 24 hUp,SCr,FIB,vWF,IL-6,BAFF,FN levels and the ratio of Th17/Treg in the treatment group were significantly lower than the control group(P<0.05),and the eGFR level was significantly higher than the control group(P<0.05).The incidence of adverse reactions in the control group and the observation group was 5.6%(2/36)and 2.8%(1/36)respectively,without statistical significance(P>0.05).Conclusion Shenqi Jiangzhuo Decoction has a significant effect on improving the levels of renal function,coagulation,inflammatory factors and interstitial fibrosis in IMN patients with spleen-kidney qi deficiency and blood stasis syndrome,which can delay the progression of IMN.

彭华东;邱思淦;林研研;黄连梅;伊仕辉;白发臣

福建中医药大学附属三明中西医结合医院,福建 三明 365001福建中医药大学附属三明中西医结合医院,福建 三明 365001福建中医药大学附属三明中西医结合医院,福建 三明 365001福建中医药大学附属三明中西医结合医院,福建 三明 365001福建中医药大学附属三明中西医结合医院,福建 三明 365001福建中医药大学附属三明中西医结合医院,福建 三明 365001

医药卫生

参芪降浊汤脾肾气虚兼血瘀证特发性膜性肾病高凝状态炎症因子肾间质纤维化

Shenqi Jiangzhuo Decoctionspleen-kidney qi deficiency and blood stasis syndromeidiopathic membranous nephropathyhypercoagulable stateinflammatory factorsrenal interstitial fibrosis

《中国中医药信息杂志》 2026 (5)

137-143,7

福建中医药大学校管科研课题(XB2023088)

10.19879/j.cnki.1005-5304.202508417

评论